why choose us

First received: July 13, 2023

Clinical Trial: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Type 2 Diabetes

Study Type: INTERVENTIONAL


Official Title: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Brief Summary: The purpose of this study is to examine the effect of empagliflozin, with and without pancreatic clamp, on endogenous (hepatic) glucose production (EGP, or 6,6, D2-glucose), gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to 3-betahydroxybutyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.

Read more